COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

Advanced search
Browse by:

Department | Year

UCL Theses | Latest

Deposit your research

COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

Brownlee, WJ; (2020) COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? Multiple Sclerosis Journal , 26 (10) p. 1267. 10.1177/1352458520948211. Green open access

Preview

Text
COVID-19 and high-efficacy multiple sclerosis therapies Time for business as usual.pdf - Published Version
Download (436kB) | Preview

Type:	Article
Title:	COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
Open access status:	An open access version is available from UCL Discovery
DOI:	10.1177/1352458520948211
Publisher version:	https://doi.org/10.1177%2F1352458520948211
Language:	English
Additional information:	© 2021 by SAGE Publications. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
Keywords:	COVID-19, multiple sclerosis
UCL classification:	UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neuroinflammation
URI:	https://discovery.ucl.ac.uk/id/eprint/10126617

Downloads since deposit

0Downloads

Download activity - last month

Download activity - last 12 months

Downloads by country - last 12 months

Archive Staff Only

View Item